New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Zoledronic acid (ZOL) is a nitrogen-containing bisphosphonate and its use in reducing osteoporosis and cancer-induced osteolysis is increasing. Recent findings indicated that ZOL has a direct effect on cancer cells. In this study, the effect of ZOL was examined on the aggressive MDA-MB-231 breast cancer cell line. ZOL induces an important inhibition of cell invasion at low concentrations (1 microM). This is not explained by modifications of proteases involved in cell invasiveness (matrix metalloproteinases and urokinase-type plasminogen activator), but by a disorganisation of actin cytoskeleton due to RhoA inhibition related to its defective prenylation as it was reversed by geranylgeraniol (GGOH) and mimicked by the Rho selective inhibitor C3 exoenzyme. In addition, ZOL inhibits the chemotactic effect induced by stromal cell-derived factor 1(SDF-1), a chemokine greatly involved in cancer metastasis to bone. This effect is related to both reduction of cell motility induced by RhoA inhibition and to a decreased expression of CXCR-4, the SDF-1 receptor. Finally, ZOL reduces Cox-2 expression and, consequently, the secretion of prostaglandins E2 (PGE2) in a RhoA-independent manner. This inhibition could contribute to bone protection in breast cancers because PGE2 stimulates osteoclast-mediated bone resorption. In summary, new insights in the mechanism of ZOL action on aggressive breast cancer cells are demonstrated and could explain its beneficial action in both the reduction of osteolysis and prevention of metastasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Involvement of chemokine receptors in breast cancer metastasis
Müller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M. E., McClanahan, T., Murphy, E., Yuan, W., Wagner, S. N., et al. (2001) · Nature · doi:10.1038/35065016 · Cited by 5,340 · cited 3×
“This effect of ZOL could be crucial for the inhibition of cancer cell metastasis in bone, as it was reported that neutralising anti-human CXCR-4 monoclonal antibody suppresses metastases in a breast-cancer model (Müller et al, 2001).”
BackgroundInfluentialThe distribution of secondary growths in cancer of the breast.
Paget, S. (1889) · The Lancet · doi:10.1016/s0140-6736(00)49915-0 · Cited by 5,277 · cited 1×
“Breast cancers preferentially metastasise into the skeleton, causing specific clinical complications: hypercalcaemia, bone fractures and pain (Paget, 1889; Mundy, 1997).”
Roodman, G. D. (2004) · New England Journal of Medicine · doi:10.1056/nejmra030831 · Cited by 2,755
Sahai, E., & Marshall, C. J. (2002) · Nature Reviews Cancer · doi:10.1038/nrc725 · Cited by 1,261 · cited 1×
“Second, the small GTPases of Ras and Rho families are widely involved in human tumorigenesis and metastasis, either through constitutive activation caused by mutations or by overexpression (Adjei, 2001; Sahai and Marshall, 2002).”
BackgroundUse of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone.
Taichman, R. S., Cooper, C. R., Keller, E. T., Pienta, K. J., Taichman, N. S., & McCauley, L. K. (2002) · PubMed · Cited by 1,118
The clinical course of bone metastases from breast cancer
Coleman, R., & Rubens, R. (1987) · British Journal of Cancer · doi:10.1038/bjc.1987.13 · Cited by 1,084 · cited 1×
“Indeed, 80% of patients with metastatic breast cancer will develop bone metastases and survive for approximately 2 years (Coleman and Rubens, 1987).”
BackgroundBisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo
Hughes, D. E., Wright, K. R., Uy, H. L., Sasaki, A., Yoneda, T., Roodman, D. G., Mundy, G. R., & Dr. Boyce, B. F. (1995) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650101008 · Cited by 1,040 · cited 1×
“In the first years of BP use, the efficacy of these substances was thought to lie entirely in the antiproliferative and apoptotic effects on osteoclasts (Hughes et al, 1995; Selander et al, 1996).”
BackgroundSato, M., Grasser, W., Endo, N., Akins, R., Simmons, H., Thompson, D. D., Golub, E., & Rodan, G. A. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115539 · Cited by 1,004 · cited 1×
“Although one study suggested that the concentration of BP could reach as high a value as 800mM at the osteoclast–bone interface (Sato et al, 1991), others reported that an estimated concentration of BP is about 1 mM in the metastatic tumour nest in bone (Usui et al, 1997).”
BackgroundYin, J. J., Selander, K., Chirgwin, J. M., Dallas, M., Grubbs, B. G., Wieser, R., Massagué, J., Mundy, G. R., & Guise, T. A. (1999) · Journal of Clinical Investigation · doi:10.1172/jci3523 · Cited by 986 · cited 1×
“1638 British Journal of Cancer (2003) 88(10), 1631 – 1640 & 2003 Cancer Research UK E x p e rim e n ta l T h e ra p e u tic s which lead to disruption of bone structure and release of stromabound factors that in turn stimulate the growth of cancer cells (Yin et al, 1999).”
BackgroundBlocking Oncogenic Ras Signaling for Cancer Therapy
Adjei, A. A. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.14.1062 · Cited by 831 · cited 1×
“Second, the small GTPases of Ras and Rho families are widely involved in human tumorigenesis and metastasis, either through constitutive activation caused by mutations or by overexpression (Adjei, 2001; Sahai and Marshall, 2002).”
Background
Cited by
Mevalonate pathway: A review of clinical and therapeutical implications
Buhaescu, I., & Izzedine, H. (2007) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2007.03.016 · Cited by 620
Terpene Biosynthesis: Modularity Rules
Oldfield, E., & Lin, F. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201103110 · Cited by 391
Organ selectivity in metastasis: regulation by chemokines and their receptors
Ben-Baruch, A. (2008) · Clinical & Experimental Metastasis · doi:10.1007/s10585-007-9097-3 · Cited by 264
Bisphosphonates and Cancer-Induced Bone Disease: Beyond Their Antiresorptive Activity
Clézardin, P., Ebetino, F. H., & Fournier, P. G. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0264 · Cited by 232
Exploring the anti-tumour activity of bisphosphonates in early breast cancer
Winter, M. C., Holen, I., & Coleman, R. E. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.02.004 · Cited by 224
Cholesterol and beyond - The role of the mevalonate pathway in cancer biology
Göbel, A., Rauner, M., Hofbauer, L. C., & Rachner, T. D. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188351 · Cited by 164
Transmigration: A New Property of Mature Multinucleated Osteoclasts
Saltel, F., Chabadel, A., Zhao, Y., Lafage-Proust, M.-H., Clézardin, P., Jurdic, P., & Bonnelye, E. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060821 · Cited by 41
Metadata
- Authors
- Denoyelle, C., Hong, L., Vannier, J.-P., Soria, J., & Soria, C.
- Venue
- British Journal of Cancer
- Published
- 2003-05
- Volume
- 88
- Issue
- 10
- Pages
- 1631-1640
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2084651782
- Cited by
- 158
- References
- 52
- FWCI
- 4.01
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.